Sex hormone-binding globulin and thrombin generation in women using hormonal contraception

Abstract Objectives: We investigated the impact of serum sex hormone-binding globulin (SHBG) on thrombin generation (TG) in women according to hormonal contraception. Patients and methods: A cross-sectional study of SHBG and TG measured via calibrated automated thrombography was conducted in 150 healthy women, including 75 users of combined oral contraceptives (COC), 22 users of progestin-only contraceptives (POC) and 53 nonusers. Results: COC but not POC-users had significantly higher SHBG levels compared with nonusers. In hormonal contraceptive users, SHBG was positively associated with both activated protein C (APC) resistance and baseline TG, and protein S and prothrombin were important mediators. Conclusion: These data provide further evidence that SHBG may be used as a biomarker in assessing prothrombotic profile of hormonal contraception.

[1]  H. Coenraad Hemker,et al.  Calibrated Automated Thrombin Generation Measurement in Clotting Plasma , 2003, Pathophysiology of Haemostasis and Thrombosis.

[2]  R. van Oerle,et al.  Coagulation factors and the protein C system as determinants of thrombin generation in a normal population , 2007, Journal of thrombosis and haemostasis : JTH.

[3]  J. Dartigues,et al.  Increased Thrombin Generation Is Associated With Acute Ischemic Stroke but Not With Coronary Heart Disease in the Elderly: The Three-City Cohort Study , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[4]  F. Rosendaal,et al.  Activated protein C resistance determined with a thrombin generation‐based test predicts for venous thrombosis in men and women , 2003, British journal of haematology.

[5]  M. Alhenc-Gelas,et al.  Increased thrombin generation among postmenopausal women using hormone therapy: importance of the route of estrogen administration and progestogens , 2011, Menopause.

[6]  F. Rosendaal,et al.  Sex hormone‐binding globulin as a marker for the thrombotic risk of hormonal contraceptives , 2012, Journal of thrombosis and haemostasis : JTH.

[7]  A. Virkkunen,et al.  The effects of two progestogen-only pills containing either desogestrel (75 μg/day) or levonorgestrel (30 μg/day) on lipid metabolism , 2001 .

[8]  D. Glintborg,et al.  Increased thrombin generation in women with polycystic ovary syndrome: A pilot study on the effect of metformin and oral contraceptives. , 2015, Metabolism: clinical and experimental.

[9]  H. Kuhl.  Comparative Pharmacology of Newer Progestogens , 1996, Drugs.

[10]  F. Rosendaal,et al.  Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens. , 2005, Human reproduction.

[11]  F. Rosendaal,et al.  Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study. , 2009, Thrombosis research.

[12]  M. Stegnar,et al.  Enhanced thrombin generation in women with a history of oral contraception-related venous thrombosis. , 2012, Thrombosis research.

[13]  T. Stijnen,et al.  Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis , 2013, BMJ : British Medical Journal.

[14]  A. Hamsten,et al.  Sex hormone--binding globulin--a surrogate marker for the prothrombotic effects of combined oral contraceptives. , 2004, American journal of obstetrics and gynecology.

[15]  M. Matsuoka.  [Coagulation factors]. , 1961, Jibi inkoka Otolaryngology.

[16]  C. Legnani,et al.  The risk of a first and a recurrent venous thrombosis associated with an elevated D‐dimer level and an elevated thrombin potential: results of the THE‐VTE study: comment , 2015, Journal of thrombosis and haemostasis : JTH.

[17]  J. Jespersen,et al.  Sex hormone‐binding globulin as a marker for the thrombotic risk of hormonal contraceptives: a rebuttal , 2013, Journal of Thrombosis and Haemostasis.

[18]  J. Rosing,et al.  Obesity and thrombin-generation profiles in women with venous thromboembolism , 2013, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[19]  A. Gompel,et al.  Epidemiology of hormonal contraceptives-related venous thromboembolism. , 2014, European journal of endocrinology.

[20]  N. Terrin,et al.  Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis , 2012, BMJ : British Medical Journal.

[21]  A. Cano,et al.  Progestin-only contraception and venous thromboembolism , 2012, Journal of Family Planning and Reproductive Health Care.

[22]  J. Hapgood,et al.  Potency of progestogens used in hormonal therapy: Toward understanding differential actions , 2014, The Journal of Steroid Biochemistry and Molecular Biology.

[23]  J. Rosing,et al.  Mechanisms of estrogen-induced venous thromboembolism. , 2010, Thrombosis research.

[24]  J. Rosing,et al.  Changes in haemostatic parameters during the menstrual cycle and subsequent use of drospirenone-containing oral contraceptives. , 2014, Thrombosis research.

[25]  K. Spanaus,et al.  Implanon use lowers plasma concentrations of high-molecular-weight adiponectin. , 2011, Fertility and sterility.

[26]  F. Rosendaal,et al.  Sex hormone‐binding globulin levels are not causally related to venous thrombosis risk in women not using hormonal contraceptives , 2012, Journal of thrombosis and haemostasis : JTH.

[27]  R. Tracy,et al.  Longitudinal Stability of Coagulation, Fibrinolysis, and Inflammation Factors in Stored Plasma Samples , 2001, Thrombosis and Haemostasis.

[28]  D. Shi,et al.  Biomarkers of deep venous thrombosis , 2012, Journal of Thrombosis and Thrombolysis.

[29]  A. Wodzicki,et al.  Chlormadinone acetate and its effect on the hemostatic mechanism. , 1972, Canadian Medical Association journal.

[30]  C. Peterson,et al.  Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives. , 1995, Contraception.

[31]  A. Virkkunen,et al.  The effects of two progestogen-only pills containing either desogestrel (75 microg/day) or levonorgestrel (30 microg/day) on lipid metabolism. , 2001, Contraception.

[32]  D. Grimes,et al.  Sex hormone-binding globulin: not a surrogate marker for venous thromboembolism in women using oral contraceptives. , 2008, Contraception.

[33]  F. Rosendaal,et al.  The risk of a first and a recurrent venous thrombosis associated with an elevated D‐dimer level and an elevated thrombin potential: results of the THE‐VTE study , 2015, Journal of thrombosis and haemostasis : JTH.

[34]  I. Persson,et al.  Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? , 2002, Acta obstetricia et gynecologica Scandinavica.

[35]  F. Rosendaal,et al.  Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography , 2007, Thrombosis and Haemostasis.

[36]  J. Hugon-Rodin,et al.  Hormonal contraceptives and venous thromboembolism: an epidemiological update. , 2013, Best practice & research. Clinical endocrinology & metabolism.

[37]  A. Schindler.  Differential effects of progestins on hemostasis. , 2003, Maturitas.